BioSpace News Archive

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 23 scientific posters, both independently and collaboratively with clients, at Neuroscience 2022, the annual meeting of the Society for Neuroscience (SfN).

Tryp Therapeutics, Inc. today announced that the Company’s collaborators from the University of Michigan will present two scientific posters in the upcoming Society for Neuroscience (SfN) Conference, to be held from November 12-16, 2022 in San Diego.

BrainStorm Cell Therapeutics Inc. today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company’s New Biologics License Application (BLA) for NurOwn for the treatment of ALS.

Inspira™ Technologies OXY B.H.N. Ltd. announced today that the Israeli Patent Office (ILPO) granted a patent for a key safety component of the INSPIRA TM ART system.

RespireRx Pharmaceuticals Inc. is pleased to announce that Jeff Margolis, Senior Vice President, Chief Financial Officer, Treasurer and Secretary is presenting a summary and update about the Company at the Investor Summit Q4 sponsored by the Investor Summit Group (https://investorsummitgroup.com), in person, on November 14, 2022 from 2:00-2:30pm EST at the Sheraton Times Square, New York, NY.

Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the third quarter and nine months ended September 30, 2022 and provided a corporate update.

Lytix Biopharma AS today announces the release of new data describing how LTX-315 treatment activates specific immune cells that are critical for a proper priming of tumor-specific T cells.

Athersys, Inc. announced today that it intends to file its quarterly report on Form 10-Q for the three months ended September 30, 2022 with the U.S. Securities and Exchange Commission (SEC) after market close on Monday, November 14, 2022, issue a news release reporting those financial results and recent business highlights before market open on Tuesday, November 15, 2022, and hold a conference call at 11:00 a.m. Eastern Time on Tuesday, November 15, 2022.

Nurix Therapeutics, Inc. presented preclinical data supporting the utility of its CBL-B inhibitors to enhance cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, which is being held November 8 – 12th in Boston.

EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data highlighting EVOLVE™, the company’s novel costimulatory T cell engager platform, were presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).